RITUXAN® (Rituximab)

The FDA on October 19, 2012 approved a 90-minute infusion for RITUXAN® (Rituximab) starting at Cycle 2 for patients with non-Hodgkin’s lymphoma (NHL) who did not experience a grade 3 or 4 infusion-related adverse reaction during Cycle 1. Patients with clinically significant cardiovascular disease and high circulating lymphocyte counts (>5000/mcL) are not recommended to receive the faster infusion. RITUXAN® is a product of Genentech, Inc.